CVRx® Barostim neo™ for Hypertension and Heart Failure

US:

About Barostim neo

Barostim neo is a second-generation device that uses CVRx-patented technology designed to trigger the body’s own natural blood flow regulation system to treat patients suffering from chronic heart failure.  The therapy is also a treatment option for patients with resistant hypertension.  The system electrically activates the baroreflex, the body’s natural mechanism to regulate cardiovascular function.  By activating this afferent pathway, Barostim Therapy® reduces sympathetic activity and increases parasympathetic activity, ultimately restoring sympatho-vagal balance.

 Key unique benefits:

  • The Barostim neo can be turned on and off to demonstrate acute results
  • It can be adjusted to meet each patient’s individual therapy needs
  • It is a reversible treatment, therapy can be turned off
  • It provides 100 percent adherence to treatment by continuously activating the baroreflex
  • It is compatible with implantable cardiac rhythm management devices¹

1. Madershahian N, et al. Baroreflex activation therapy in patients with preexisting implantable cardioverter-defibrilator: Compatible, complementary therapies. EuropaceFeb, 2014


OUS:

About Barostim neo

Barostim neo is a second-generation device that uses CVRx-patented technology designed to trigger the body’s own natural blood flow regulation system to treat patients suffering from chronic heart failure.  The therapy is also a safe and efficacious treatment option for patients with resistant hypertension.  The system electrically activates the baroreflex, the body’s natural mechanism to regulate cardiovascular function.  By activating this afferent pathway, Barostim Therapy® reduces sympathetic activity and increases parasympathetic activity, ultimately restoring sympatho-vagal balance.

 Key unique benefits:

  • The Barostim neo can be turned on and off to demonstrate acute results
  • It can be adjusted to meet each patient’s individual therapy needs
  • It is a reversible treatment
  • It provides 100 percent adherence to treatment by continuously activating the baroreflex
  • It is compatible with and complementary to implantable cardiac rhythm management devices¹
  • It is now MR Conditional, or safe for use under specified conditions

1. Madershahian N, et al. Baroreflex activation therapy in patients with preexisting implantable cardioverter-defibrilator: Compatible, complementary therapies. EuropaceFeb, 2014

 

Supplier
CVRx®, Inc.

Image: 

CVRx® Barostim neo™ for Hypertension and Heart Failure